Table 1.

Characteristics of patient cases. Shown per patient are primary tumor, treatment, capecitabine dose, executed assays (genotype, dihydropyrimidine dehydrogenase (DPD) enzyme activity, and additional assays) information. Additional assays are droplet digital PCR, PacBio sequencing (Menlo Park, CA, USA), or an in-house developed technique. For the executed assays, it is shown whether these were executed prior to treatment (P) or retrospectively (R). Abbreviations: BC: breast cancer; CRC: colorectal cancer; CAP: capecitabine; RT: radiotherapy; OX: oxaliplatin; BEV: bevacizumab; bid: bis in die/twice a day.

Patient #	Primary Tumor	Treatment	Capecitabine Dose	Executed Assays
1	BC	CAP	1000 mg/m2/bid	Genotyping (R), DPD activity (R), in-house technique (R), droplet digital PCR (R)
2	BC	CAP	800 mg bid (50%)	Genotyping (P), DPD activity (R), in-house technique (R)
3	CRC	CAP + OX	900 mg bid (50%) 1	Genotyping (P), DPD activity (P), PacBio (R)
4	BC	CAP	1500 mg bid	Genotyping (R), DPD activity (R 2)
5	CRC	CAP + RT	800 mg bid (50%)	Genotyping (P + R 3), DPD activity (R 4), PacBio (R)
6	CRC	CAP + OX	1000 mg/m2/bid	Genotyping (R), DPD activity (R)
7	CRC	CAP + OX + BEV	1000 mg/m2/bid	Genotyping (R), DPD activity (R)

¹ Increased to 70% in the second cycle; ² during hospital admission; ³ DPYD*2A was prospectively identified, c.2846A>T was retrospectively identified; ⁴ during treatment.